Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arjo ABARRJF 69 EV-to-EBITDA is 3.98 as of Aug. 05, 2026, which is 54% below its 10-year median of 8.72. GuruFocus rates ARRJF with a GF Score™ of 69/100 and a GF Value™ of $3.59 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 98 Medical Distribution companies, Arjo AB ranks better than 83.67% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Arjo AB's enterprise value is $825 Mil.
Arjo AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $207 Mil. Therefore, Arjo AB's EV-to-EBITDA for today is 3.98.
The historical rank and industry rank for Arjo AB's EV-to-EBITDA or its related term are showing as below:
ARRJF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.55 Med: 8.72 Max: 17.58
Current: 3.98
During the past 13 years, the highest EV-to-EBITDA of Arjo AB was 17.58. The lowest was 3.55. And the median was 8.72.
ARRJF's EV-to-EBITDA is ranked better than 83.67% of 98
companies
in the Medical Distribution industry
Industry Median: 8.59
vs ARRJF: 3.98
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Arjo AB's share price for today is $2.85.
Arjo AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.151.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Arjo AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Arjo AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arjo AB EV-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Arjo AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Arjo AB's EV-to-EBITDA falls into.
Arjo AB's current Enterprise Value is $825 Mil.
Arjo AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $207 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arjo AB (ARRJF) has a EV-to-EBITDA of 3.98 as of Aug. 05, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Arjo AB. This is 54% below median its historical median of 8.72. Over the past decade, Arjo AB's EV-to-EBITDA has ranged from 3.55 to 17.58. According to the industry distribution chart, Arjo AB ranks #16 out of 98 companies in the Medical Distribution industry, placing it in the top 16.3%.
Is Arjo AB's EV-to-EBITDA too high?
Arjo AB's current EV-to-EBITDA of 3.98 is 54% below median its 10-year median of 8.72. Over the past 10 years, this metric has ranged from a low of 3.55 to a high of 17.58. The Medical Distribution industry median EV-to-EBITDA is 8.59. Arjo AB's value of 3.98 is 53.7% below this industry median. Based on the distribution chart, Arjo AB ranks #16 out of 98 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Arjo AB has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Arjo AB's EV-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Arjo AB ranks #16 out of 98 companies for EV-to-EBITDA. This places Arjo AB in the top 16% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 8.59. Arjo AB's value of 3.98 is 53.7% below this benchmark. Historically, Arjo AB's own EV-to-EBITDA has ranged from 3.55 to 17.58 over the past decade. While the company's 10-year median is 8.72 vs. the industry median of 8.59, Arjo AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Distribution company?
The median EV-to-EBITDA among Medical Distribution companies is 8.59, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arjo AB's current EV-to-EBITDA of 3.98 is 53.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Arjo AB. For the Medical Distribution industry, the median EV-to-EBITDA is 8.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arjo AB's current EV-to-EBITDA is 3.98, which is 54% below median its own 10-year median of 8.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arjo AB stock overvalued right now?
Based on GuruFocus' analysis, Arjo AB (ARRJF) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.59, compared to a current price of $2.85 — trading 20.6% below its estimated fair value. The current EV-to-EBITDA is 3.98, which is 54% below median its 10-year median of 8.72 and 53.7% below the Medical Distribution industry median of 8.59. Arjo AB's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Arjo AB (ARRJF), the current EV-to-EBITDA is 3.98 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arjo AB (ARRJF) Overvalued in 2026?
Based on GuruFocus' analysis, Arjo AB stock appears to be undervalued.
The current stock price of $2.85 is trading 20.6% below its estimated GF Value™ of $3.59.
GuruFocus considers Arjo AB to be Modestly Undervalued.
Key valuation signals for ARRJF:
EV-to-EBITDA: 3.98 (54% below median its 10-year median of 8.72)
GF Value™: $3.59 vs. price of $2.85 (20.6% below fair value)
Industry Position: 53.7% below the Medical Distribution median (#16 of 98)
No single metric tells the full story. See the ARRJF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arjo AB is a supplier of medical devices, services, and solutions in Sweden. It serves its services to private and public institutions with acute care and long-term care. The company's offering includes products and solutions for patient handling, hygiene, disinfection, medical beds, therapeutic surfaces, venous thromboembolism (VTE) prevention and diagnostics. The company includes segments: Global Sales, North America, Diagnostics.
69GF Score
Get the complete analysis for ARRJF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARRJF has been successfully added to your 
